Abstract
Pancreatic carcinoma-1 (PANC-1) is a human pancreatic cancer cell line derived from a pancreatic ductal adenocarcinoma (PDAC) tumor, often used in research to study pancreatic cancer biology, molecular mechanisms, and potential therapeutic interventions. PANC-1 cells exhibit genetic alterations characteristic of pancreatic cancer, such as mutations in the KRAS oncogene and TP53 tumor suppressor gene. Cultured in vitro, these cells enable researchers to investigate the effects of treatments, genetic manipulations, or signaling pathway modulations on cancer cell growth, survival, and migration. This Patent Highlight discloses new compounds capable of inhibiting KRAS(G12D) proteins, potentially useful in treating KRAS(G12D)-associated diseases, such as pancreatic cancer.